F

or an early-stage biotech company, raising venture capital funding for the first time is a crucial milestone. And when you look at all the baby’s-first-financing announcements of the past few years, there’s something going on that Atlas Venture VC Bruce Booth calls “so counterintuitive in a lot of ways.”

New data show that the number of life sciences companies that reach that pivotal moment has stayed flat over the past few years. But the amount of money being invested in these first financings is rising, indicating that when companies do manage to get a first big investment, they’re getting more money. The figures come from PitchBook, a company that analyzes and sells data on the private markets.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.